Equillium (LTS:0A4D) Interest Expense : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Equillium Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Equillium's interest expense for the three months ended in Dec. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Equillium's Operating Income for the three months ended in Dec. 2024 was $ -4.70 Mil. Equillium's Interest Expense for the three months ended in Dec. 2024 was $ 0.00 Mil. GuruFocus does not calculate Equillium's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Equillium Interest Expense Historical Data

The historical data trend for Equillium's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Equillium Interest Expense Chart

Equillium Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-1.10

-1.07

-1.05

-0.49

Equillium Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Equillium Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Equillium (LTS:0A4D) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Equillium's Interest Expense for the three months ended in Dec. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2024 was $-4.70 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2024 was $0.19 Mil.

Equillium's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

GuruFocus does not calculate Equillium's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Equillium Inc has enough cash to cover all of its debt. Its financial situation is stable.

Equillium Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (LTS:0A4D) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

EQ:USA 0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Equillium Headlines

No Headlines